Keyword: University of California San Francisco
Broad Institute scientists have created an RNA-editing method that makes reversible changes to DNA possible.
The past week brought discoveries related to tumor metastasis, the virulence of a superbug, and breast cancer risk.
A "blunted" version of CRISPR can be used to identify gene regulators in the genome and help unravel autoimmune disease.
UCSF scientist Shaun Coughlin will lead CV research at NIBR, Novo's China GM was promoted to EVP, and Cavion poached Teva exec to head up R&D.
The director of UCSF's Cardiovascular Research Institute—Shaun Coughlin, M.D., Ph.D.—has joined the ranks of senior academics heading to drugmaker Novartis.
Anti-CRISPR proteins may be the key to preventing harmful side effects from off-target editing.
Most research aimed at finding an HIV cure is focused on wiping out the virus from immune cells, but a new discovery suggests a different approach is in order.
Numares launched its noninvasive urine test for kidney rejection, the first to use a metabolic biomarker network rather than just one.
Insufficient enrollment is one of the biggest challenges for clinical trials. A new patients finder tool has been launched by UCSF to help connect clinical researchers at the university with patients.
A team at the University of California in San Francisco has brought a large-scale version of CRISPR gene editing to the fight against HIV infection, offering possibilities for both the discovery of new techniques and the ability to treat those with the virus.